Adipose-Derived Stem Cells Inhibited the Proliferation of Bladder Tumor Cells by S Phase Arrest and Wnt/β-Catenin Pathway.

Tao Wang,Tao Xu,Lei Wang,Jian Lin,Tao Bai,Xiuheng Liu,Shenglan Li,Cong Qin,Xi Yu

doi:10.1089/cell.2019.0047

Tao Wang, Tao Xu + Show 7 more

Open Access

https://doi.org/10.1089/cell.2019.0047

Copy DOI

Abstract

Adipose-derived stem cells (ADSCs), which are present in most organs and tissues, were evaluated as a novel medium for stem cell therapy. In this study, we investigated the effects and underlying mechanisms of ADSCs in bladder tumor (BT) cells. SV-HUC, T24, and EJ cells were cultured with ADSCs and conditioned medium from ADSCs (ADSC-CM). We observed that in routine culture, ADSCs significantly inhibited the proliferation of T24 and EJ cells in a dose-dependent manner. In addition, ADSC-CM attenuated the viability of T24 and EJ cells in a dose-dependent manner. Cell cycle analysis indicated that ADSC-CM was capable of inducing T24 and EJ cells S phase arrest and downregulating the expression of CDK 1, whereas the expression of cyclin A was increased. ADSC-CM could induce apoptosis in T24 cells. The mechanism of this effect likely involved the caspase3/7 pathway and Wnt/β-catenin pathway. These findings demonstrated that ADSCs could inhibit the proliferation of BT cells via secretory factors.

Highlights

In 2018, bladder tumor (BT) was the second most common malignancy of the genitourinary tract with almost 80,000 newly diagnosed cases and almost 17,000 deaths in the USA (Siegel et al, 2019)
Adipose-derived stem cells (ADSCs)-CM showed no significant inhibition in SV-HUC (Fig. 1B) cells, but inhibited the viability of T24 (Fig. 1D) and EJ (Fig. 1F) cells in a dosedependent manner compared to that observed in control cells
The western blot showed that cyclin A level was increased and CDK1 level was decreased in ADSC-CM-treated T24 and EJ cells, but not in SV-HUC cells (Fig. 2A)

Summary

Introduction

In 2018, bladder tumor (BT) was the second most common malignancy of the genitourinary tract with almost 80,000 newly diagnosed cases and almost 17,000 deaths in the USA (Siegel et al, 2019). The treatment schemes for BT such as surgical techniques, including minimally invasive surgery are various, and there has been an improvement in the understanding of multimodal treatments involving radiotherapy, chemotherapy, and immunotherapy (DeGeorge et al, 2017). These treatments are considered costly and bring a huge economic burden to patients. There is debate over the ability of ADSCs to support or suppress tumor cell proliferation (Chu et al, 2015; Jing et al, 2016; Yu et al, 2015)

Methods

Results

Conclusion